20/20 BioLabs, Inc. (AIDX) reported its financial results for the first quarter, reflecting a revenue slip for the period ending March 31, 2026.
Meanwhile, looking ahead to the second quarter of 2026, the firm said that, based on expected fulfilment of state-funded firefighter screening orders, it expects revenue to rebound.
Company Profile
20/20 Biolabs develops and commercialises laboratory-based blood tests for the early detection of cancers and chronic diseases.
The firm's OneTest for cancer is a multi-cancer early detection (MCED) blood test, and OneTest for Longevity measures inflammatory biomarkers.
First Quarter Results
For the first quarter, net loss expanded to $2.17 million or $0.28 per share, compared to $0.76 million or $0.16 per share in the prior year.
Total revenue slipped to $0.35 million from $0.55 million a year ago. The decline was primarily due to the timing of orders from several larger customers, according to the firm.
As of March 31, cash and cash equivalents totalled $4.22 million.
AIDX has traded between $1.25 and $50.00 over the last year. The stock closed Wednesday's trade at $1.29, down $43.74. AIDX is currently up 3.10% at $1.33 in the overnight market.
For more such news For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.